Close

VSIV VSV8

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This octapeptide is amino acids 52 to 59 fragment of the the vesicular stomatitis virus (VSV) nucleoprotein. VSV-8 is derived from the VSV nucleoprotein that is expressed in the cytosol of the infected cells. CTL response against VSV in H-2Kb mice is directed against this single VSV-8 immunodominant peptide. This peptide forms complex with murine MHC class I molecule H-2Kb, which is similar to human HLA class I.
  • TCR Cell Products

Loading...
  • Cell Type:
  • Target:
  • HLA:
  • Epitope:
CAT Product Name Cell Type Target HLA Epitope Inquiry & Datasheet
TCRJ-CQ467 Anti-VSIV VSV8 (RGYVYQGL) T Cell Receptor (clone BM3.3), Jurkat Cell Line T lymphocyte VSIV VSV8 H-2Kb RGYVYQGL   Add to Cart   Datasheet
TCRJ-CQ468 Anti-VSIV VSV8 (RGYVYQGL) T Cell Receptor (clone N15), Jurkat Cell Line T lymphocyte VSIV VSV8 H-2Kb RGYVYQGL   Add to Cart   Datasheet
XS-0623-ZP194 Anti-VSIV VSV8 TCR-NK Cells TCR-NK VSIV VSV8   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.